Osteonecrosis of the jaw. A newly emerging site-specific osseous pathology in patients with cancer treated with bisphosphonates. Report of five cases and review of the literature

European Journal of Internal Medicine

Volumn 18, Issue 5, 2007, Pages 417-422

  Cavanna, Luigi ^a   Bertè, Raffaella ^a   Arcari, Annalisa ^a   Mordenti, Patrizia ^a   Pagani, Raffaella ^a   Vallisa, Daniele ^a  

^a Hospital of Piacenza   (Italy)

Author keywords

Bisphosphonates; Cancer metastasis; Jaw; Mandible; ONJ; Osteonecrosis

Indexed keywords

ALENDRONIC ACID; ANALGESIC AGENT; ANTIBIOTIC AGENT; ANTINEOPLASTIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CHLORHEXIDINE; CORTICOSTEROID; IBANDRONIC ACID; PAMIDRONIC ACID; RISEDRONIC ACID; TETRACYCLINE; ZOLEDRONIC ACID;

ADULT; ADVANCED CANCER; AGED; ARTICLE; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BONE CANCER; BONE NECROSIS; BONE PAIN; BREAST CANCER; CLINICAL ARTICLE; CLINICAL FEATURE; CONSERVATIVE TREATMENT; DENTAL CARE; DENTAL SURGERY; DRUG WITHDRAWAL; FEMALE; HUMAN; JAW DISEASE; JAW OSTEONECROSIS; JAW RADIOGRAPHY; KIDNEY CARCINOMA; MANDIBLE; MAXILLA; MOUTH HYGIENE; MULTIPLE MYELOMA; OSTEOPOROSIS; PATIENT COUNSELING; PLEURA MESOTHELIOMA; PROTECTIVE EQUIPMENT; TREATMENT DURATION; TREATMENT INDICATION;

EID: 34547663269     PISSN: 09536205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejim.2006.10.008     Document Type: Article

References (31)

1. Hultborn R., Gundersen S., Ryden S., Holmberg E., Carstensen J., Wallgren U.B., et al. Efficacy of pamidronate in breast cancer with bone metastases: a randomised, double-blind placebo-controlled multicenter study. Anticancer Res 19 (1999) 3383-3392
2. Lipton A., Theriault R.L., Hortobagyi G.N., Simeone J., Knight R.D., Mellars K., et al. Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomised, placebo-controlled trials. Cancer 88 (2000) 1082-1090
3. Rosen L.S., Gordon D., Kaminski M., Howell A., Belch A., Mackey J., et al. Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomised, double-blind, multicenter, comparative trial. Cancer 98 (2003) 1735-1744
4. Saad F., Gleason D.M., Murray R., Tchekmedyian S., Venner P., Lacombe L., et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 96 (2004) 879-2
5. Marx R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61 (2003) 1115-1117
6. Migliorati C.A. Bisphosphonates and oral cavity avascular bone necrosis. J Clin Oncol 21 (2003) 4253-4254
7. Ruggiero S.L., Mehrotra B., Rosenberg T.J., and Engroff S.L. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62 (2004) 527-534
8. Estillo C.L., Van Poznak C.H., Williams C.H., Evtimovska E., Tkach L., Halpern J.L., et al. Osteonecrosis of the maxilla and mandible in patients treated with bisphosohonates: a retrospective study [abstract]. J Clin Oncol 23 (2004) 750S (Suppl)
9. Wang J., Goodger N.M., and Pogrel M.A. Osteonecrosis of the jaws associated with cancer chemotherapy. J Oral Maxillofac Surg 61 (2003) 1104-1107
10. Durie B.G.M., Katz M., McCoy J., and Crowley J. Osteonecrosis of the jaws in myeloma: time dependent correlation with Aredia and Zometa use [abstract]. Blood 104 (2004) 216A (Suppl)
11. Thakkar S.G., Isada C., Smith J., Karam M.A., Reed J., Tomford J.W., et al. Bisphosphonate therapy associated with an increased incidence of mandibular/maxillary osteomyelitis in multiple myeloma patients [abstract]. Blood 104 (2004) 313B (Suppl)
12. Schuster M.W., and Dymek J.M. Oral cavity avascular bone necrosis: a newly recognized complication of intravenous (IV) bisphosphonate therapy in cancer patients [abstract]. Blood 104 (2004) 308B (Suppl)
13. Kut V., Mehta J., Tariman J., Olsson A., and Singhal M.D. Osteonecrosis of the jaw in myeloma patients receiving pamidronate and zoledronate [abstract]. Blood 104 (2004) 315B (Suppl)
14. Van Poznak C.H., Estillo C.L., Sauter M.P., Hudis C.A., Williams T., Tunick T., et al. Osteonecrosis of the jaw in patients with metastatic breast cancer [abstract]. Breast Cancer Res Treat 88 (2004) 131S (Suppl)
15. Carter G., Goss A.N., and Doecke C. Bisphosphonates and vascular necrosis in the jaw: a possible association. Med J Aust 182 (2005) 413-415
16. Bagan J.V., Murillo J., Jimenez Y., Poveda R., Milian M.A., Sanchis J.M., et al. Avascular jaw osteonecrosis in association with cancer chemotherapy: series of 10 cases. J Oral Pathol Med 34 (2005) 120-123
17. Melo M.D., and Obeid G. Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy. J Can Dent Assoc 71 (2005) 111-113
18. Purcell P.M., and Boyd I.W. Bisphosphonates and osteonecrosis of the jaw. Med J Aust 182 (2005) 417-418
19. Zarychanski R., Elphee E., Walton P., and Johnston J. Osteonecrosis of the jaw associated with pamidronate therapy. Am J Hematol 81 (2006) 73-75
20. Badros A., Weikel D., Salama A., Goloubeva O., Schneider A., Rapoport A., et al. Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors. J Clin Oncol 24 (2006) 945-952
21. Migliorati C.A., Schubert M.M., Peterson D.E., and Seneda L.M. Bisphosphonate-associated osteonecrosis of mandibular and maxillary bone: an emergine oral complication of supportive cancer therapy. Cancer 104 (2005) 83-93
22. Hansen T., Kunkel M., Weber A., and James Kirkpatrick C. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. J Oral Pathol Med 35 (2006) 155-160
23. Ruggiero S., Gralow J., Marx R.E., Hoff A.O., Schubert M.M., Huryn J.M., et al. Practical guidelines for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in patients with cancer. J Oncol Prac 2 (2006) 7-14
24. Expert panel recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaws: June 2004. professional education material: Novartis, June 2004.
25. Reszka A.A., Halasy-Nagy J., and Rodan G.A. Nitrogen-bisphosphonates block retinoblastoma phosphorylation and cell growth by inhibiting the colesterol biosynthesis pathway in keratinocyte model for esophageal irritation. Mol Pharmacol 59 (2001) 193-2002
26. Agarwala S., Jain D., Joshi V.R., and Sule A. Efficacy of alendronate, a bisphosphonate, in the treatment of AVN of the Hip: a prospective open-label study. Rheumatology 44 (2005) 352-359
27. Polizzotto M.N., Cousins V., and Schwarer A.P. Bisphosphonate-associated osteonecrosis of the auditory canal. Br J Haematol 132 (2006) 114
28. Peters E., Lovas G.L., and Wysocki G.P. Lingual mandibular sequestration and ulceration. Oral Surg Oral Med Oral Pathol 75 (1993) 739-743
29. Bamias A., Kastritis E., Bamia C., Moulopoulos L.A., Melakopoulos I., Bozas G., et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol 23 (2005) 8580-8587
30. Jones J.R., Lehtinen T., Riphagen F.E., and von Roemeling R. Adverse event (AE) reporting of oral clodronate with emphasis on osteonecrosis of the iaws [abstract]. Presented at the annual meeting of the American Society for clinical oncology (2005) 799 Abstract
31. Chiandussi S., Biasotto M., Dore F., Cavalli F., Cova M.A., and Di Lenarda R. Clinical and diagnostic imaging of bisphosphonate-associated osteonecrosis of the jaws. Dentomaxillofac Radiol 35 4 (2006) 236-243